Werewolf Therapeutics (NASDAQ:HOWL) Shares Cross Below 50 Day Moving Average – Should You Sell?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.98 and traded as low as $0.97. Werewolf Therapeutics shares last traded at $0.97, with a volume of 217,807 shares changing hands.

Analyst Ratings Changes

HOWL has been the topic of several recent research reports. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Price Performance

The company has a market cap of $47.63 million, a price-to-earnings ratio of -1.29 and a beta of 0.55. The business’s fifty day moving average price is $0.98 and its 200 day moving average price is $0.70.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at $112,000. Covestor Ltd acquired a new stake in shares of Werewolf Therapeutics during the third quarter worth $124,000. Squarepoint Ops LLC acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth $37,000. BlackRock Inc. bought a new position in Werewolf Therapeutics during the second quarter worth $37,000. Finally, Vontobel Holding Ltd. bought a new position in Werewolf Therapeutics during the third quarter worth $55,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.